Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24837121 | 0.88 | VCP (1.00) | VCPLMNAEPAS1MAPTRXFP1 | |
| SCHEMBL8976661 | 0.76 | ALDH1A1 (0.77) | VCPLMNAEPAS1MAPTRXFP1 | |
| SCHEMBL28619635 | 0.76 | EPAS1 (0.71) | VCPLMNAEPAS1MAPTRXFP1 | |
| SCHEMBL30431601 | 0.76 | EPAS1 (0.71) | VCPLMNAEPAS1MAPTRXFP1 | |
| SCHEMBL10970617 | 0.74 | RAB9A (0.85) | LMNAMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL28631021 | 0.73 | MAPT (1.00) | VCPLMNAEPAS1MAPTRXFP1 | |
| SCHEMBL28627604 | 0.72 | LMNA (0.65) | VCPLMNAEPAS1MAPTRXFP1 | |
| SCHEMBL30430202 | 0.72 | LMNA (0.65) | VCPLMNAEPAS1MAPTRXFP1 | |
| SCHEMBL28620603 | 0.70 | ALDH1A1 (0.63) | VCPLMNAEPAS1MAPTRXFP1 | |
| SCHEMBL30430973 | 0.70 | ALDH1A1 (0.63) | VCPLMNAEPAS1MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION AND TARGETING OF P97 | CALIFORNIA INST OF TECHN (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146923-A1 | COMPOSITIONS AND METHODS FOR INHIBITION AND TARGETING OF P97 | HSP90B1, CDC37, HDLBP | VCP 29/4885LMNA 550/4885EPAS1 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.